Cellectis Competitors

Pink Sheets . USA . 
Stock . Cellectis SA
CMVLF Stock  USD 4.40  0.00  0.00%   
Cellectis SA competes with Immutep, Transgene, Frontage Holdings, Cytodyn, and Hansa Biopharma; as well as few others. The company classifies itself under Healthcare sector and is part of Biotechnology industry. Analyzing Cellectis competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Cellectis to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Cellectis Correlation with its peers.

Cellectis vs Healios KK Correlation

Poor diversification

The correlation between Cellectis SA and HLOSF is 0.75 (i.e., Poor diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Cellectis SA and HLOSF in the same portfolio, assuming nothing else is changed.

Moving against Cellectis Pink Sheet

  0.89MRK Merck Company Aggressive PushPairCorr
  0.84REGN Regeneron PharmaceuticalsPairCorr
  0.78SHPHF Sihuan PharmaceuticalPairCorr
  0.72VRTX Vertex Pharmaceuticals Earnings Call TodayPairCorr
  0.61FCAP First Capital Normal TradingPairCorr
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
3.004.405.80
Details
Intrinsic
Valuation
LowRealHigh
3.164.565.96
Details
Naive
Forecast
LowNextHigh
3.114.515.91
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
4.404.404.40
Details

Cellectis Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cellectis and its competitors represents the degree of relationship between the price movements of corresponding pink sheets. A correlation of about +1.0 implies that the price of Cellectis and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cellectis SA does not affect the price movement of the other competitor.

High positive correlations

TRGNF
+ 0.73
PRRUF
CLVLF
+ 0.6
TRGNF
CLVLF
+ 0.46
NWBO
CLVLF
+ 0.4
PRRUF
NWBO
+ 0.4
TRGNF
HLOSF
+ 0.36
HNSBF
  

High negative correlations

HLOSF
- 0.9
TRGNF
HLOSF
- 0.86
PRRUF
HLOSF
- 0.59
CLVLF
CLVLF
- 0.59
HNSBF
HLOSF
- 0.54
NWBO
NWBO
- 0.49
SLNCF

Risk-Adjusted Indicators

There is a big difference between Cellectis Pink Sheet performing well and Cellectis Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cellectis' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
PRRUF  1.89  0.47  0.00  1.46  0.00 
 0.00 
 3.85 
 0.00 
 60.76 
TRGNF  1.62  0.65  0.00  0.55  0.00 
 0.00 
 0.00 
 0.00 
 61.69 
FGHQF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CYDY  2.82  0.08  0.01 (0.53) 2.89 
(6.29)
 8.00 
(5.71)
 24.19 
HNSBF  1.09 (0.54) 0.00  1.27  0.00 
 0.00 
 0.00 
 0.00 
 36.46 
SLNCF  2.36  0.05  0.00  0.06  0.00 
 0.00 
 11.11 
 0.00 
 58.78 
NWBO  2.95  0.37  0.07  0.68  2.92 
(5.81)
 4.35 
(4.17)
 38.34 
PBBIF  0.00  0.00  0.00  0.00  0.00 
 0.00 
 0.00 
 0.00 
 0.00 
CLVLF  0.77  0.32  0.00 (0.58) 0.00 
 0.00 
 1.75 
 0.00 
 14.74 
HLOSF  1.63 (0.69) 0.00  0.73  0.00 
 0.00 
 0.00 
(6.34)
 26.47 

Cellectis Competitive Analysis

The better you understand Cellectis competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cellectis' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cellectis' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
CMVLF PRRUF TRGNF FGHQF CYDY HNSBF SLNCF NWBO CLVLF HLOSF
 0.00 
 4.40 
Cellectis
 0.00 
 0.25 
Immutep
 0.00 
 1.00 
Transgene
 0.00 
 0.15 
Frontage
 4.00 
 0.24 
Cytodyn
 0.00 
 2.91 
Hansa
 6.67 
 1.60 
Silence
 3.45 
 0.28 
Northwest
 0.36 
 8.45 
Clinuvel
 0.00 
 2.10 
Healios
Market Volatility
(90 Days Market Risk)
Somewhat reliable
Out of control
Abnormally volatile
Very steady
Out of control
Very risky
Extremely Dangerous
Out of control
Not too volatile
Very risky
Market Performance
(90 Days Performance)
Weakest
Mild
Fair
Weakest
Weakest
Weakest
Soft
Soft
Fair
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Low
Strong
Low
Risky
Small
High
Moderate
Low
Small
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Over Valued
Under Valued
Over Valued
Over Valued
Fairly Valued
Over Valued
Fairly Valued
Under Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Hold
Strong Sell
Strong Buy
Strong Sell
Strong Sell
Strong Sell
Buy
Strong Sell
Sell
Strong Sell
Current Ratio
3.17
14.16
4.27
1.81
0.08
6.42
3.76
0.1
10.24
6.01
Net Asset
382.08 M
148.52 M
101.84 M
475.84 M
29.18 M
1.01 B
96.19 M
40.16 M
143.95 M
23.97 B
Profit Margin
N/A
N/A
-1.27
0.1
N/A
N/A
-2.24
52.11
0.32
N/A
EBITDA
(103.2 M)
(43.69 M)
(16.55 M)
27.64 M
(157.59 M)
(538.83 M)
(45.42 M)
184.72 M
37.35 M
(3.4 B)
Operating Margin
-6.01
-7.18
-1.39
0.14
N/A
N/A
-2.99
-54.95
0.54
-136.9
Current Valuation
82.79 M
142.99 M
152.15 M
601.13 M
286.7 M
189.89 M
240.14 M
1.03 B
635.56 M
131.57 M
Price To Book
0.79
2.81
0.0177
2.07
1066.03
6.59
8.36
N/A
8.27
11.65
Retained Earnings
(206 M)
(222 M)
(500 M)
N/A
(211.86 M)
N/A
N/A
(862.01 M)
(133 M)
(21.04 M)
Current Asset
297 M
22 M
51 M
N/A
136.91 K
105 M
N/A
24.1 M
20 M
368 K
Beta
2.0
1.95
0.79
0.75
0.2
0.88
0.85
-0.0115
0.82
0.91
Number Of Employees
294
17
143
1.5 K
23
150
105
19
11
116
Shares Outstanding
55.59 M
879.09 M
100.2 M
2.05 B
832.97 M
52.44 M
107.68 M
1.05 B
49.41 M
60.62 M
Cash Flow From Operations
(104.56 M)
(30.23 M)
(31.94 M)
44.55 M
(77.72 M)
(481.17 M)
6.81 M
(38.3 M)
39.87 M
(5.09 B)
Annual Yield
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.0016
N/A
Total Debt
18.77 M
2.11 M
N/A
67.35 M
37.35 M
N/A
52 K
25.16 M
1.26 M
6.82 B
Return On Equity
-0.56
-0.38
-0.36
0.0719
N/A
-0.89
-1.43
N/A
0.19
-0.68
Z Score
4.2
47.2
-5.6
5.4
-22.7
N/A
N/A
-0.6
N/A
N/A
Return On Asset
-0.24
-0.23
-0.16
0.0435
-1.48
-0.27
-0.28
-1.26
0.18
-0.17
Book Value Per Share
3.0
0.11
0.55
0.16
-0.14
1.5
0.95
-0.1
2.54
77.68
Number Of Shares Shorted
N/A
N/A
N/A
N/A
N/A
N/A
N/A
14.14 M
N/A
N/A
Current Liabilities
58 M
1000 K
24 M
N/A
508.07 K
19 M
N/A
64.93 M
2 M
232 K
Total Asset
382.08 M
148.52 M
101.84 M
475.84 M
29.18 M
1.01 B
96.19 M
40.16 M
143.95 M
23.97 B
Debt To Equity
0.52
0.018
0.25
0.21
N/A
2.29
0.022
-16.14
0.01
1.61
Target Price
N/A
N/A
N/A
6.62
4.0
N/A
938.67
5.0
N/A
N/A
Short Ratio
N/A
N/A
N/A
N/A
N/A
N/A
N/A
13.54
N/A
N/A
Last Dividend Paid
N/A
N/A
N/A
N/A
N/A
N/A
N/A
N/A
0.04
N/A
Shares Owned By Institutions
9.8
24.04
1.7
15.32
0.06
41.33
27.7
0.23
8.77
14.09
Market Capitalization
131.39 M
171.77 M
212.74 M
670.64 M
233.23 M
274.8 M
349.96 M
705.3 M
835.03 M
882.08 M
Price To Earning
-13.64
-2.5
-7.42
32.66
-3.14
-46.57
-17.5
58.17
34.88
3.68
Price To Sales
4.79
33.12
10.71
3.07
1174.39
16.29
21.67
858.96
10.65
21.51
Net Income
(114.2 M)
(32.21 M)
(19.54 M)
18.43 M
(210.82 M)
(548.28 M)
(39.41 M)
179.13 M
20.88 M
(4.91 B)
Earnings Per Share
-2.95
-0.024
-0.23
0.01
-0.22
-0.65
-0.53
-0.063
0.28
-0.8
Shares Owned By Insiders
N/A
4.61
N/A
60.36
7.91
7.37
56.74
10.04
20.55
51.19
Revenue
57.29 M
247.66 K
9.99 M
184.44 M
266 K
33.88 M
12.41 M
1 M
65.72 M
41 M
Working Capital
239 M
21 M
27 M
N/A
(371.16 K)
86 M
N/A
(40.83 M)
18 M
136 K
Cash And Equivalents
153.13 M
80 M
49.57 M
72.3 M
4.68 M
60.15 M
51.56 M
9.43 M
121.51 M
12.28 B
Cash Per Share
3.37
0.09
0.5
0.04
0.01
1.58
0.57
0.01
2.46
237.66
Gross Profit
34.18 M
(26.63 M)
(15.87 M)
66.7 M
(73.28 M)
116.05 M
4.96 M
1 M
56.92 M
41 M
Day Typical Price
4.4
0.25
1.0
0.15
0.25
2.91
1.6
0.29
8.45
2.1
Accumulation Distribution
N/A
N/A
N/A
N/A
53738.0
N/A
N/A
151783.0
N/A
N/A
Daily Balance Of Power
0.0
0.0
0.0
0.0
(0.50)
0.0
9.2 T
(0.50)
9.2 T
0.0
Period Momentum Indicator
N/A
N/A
N/A
N/A
(0.01)
N/A
0.1
(0.01)
0.03
N/A
Rate Of Daily Change
1.0
1.0
1.0
1.0
0.96
1.0
1.07
0.97
1.0
1.0
Day Median Price
4.4
0.25
1.0
0.15
0.25
2.91
1.6
0.29
8.45
2.1
Price Action Indicator
N/A
N/A
N/A
N/A
(0.01)
N/A
0.05
(0.01)
0.015
N/A
Relative Strength Index
N/A
50.61
82.61
N/A
43.23
N/A
50.46
52.79
85.83
23.52
Coefficient Of Variation
(685.06)
1201.14
951.45
N/A
4916.52
(812.40)
4597.3
1200.67
601.65
(568.10)
Mean Deviation
0.3801
1.89
1.62
N/A
2.82
1.09
2.36
2.95
0.7722
1.63
Jensen Alpha
(0.22)
0.4733
0.6454
N/A
0.0822
(0.54)
0.049
0.3738
0.3233
(0.69)
Total Risk Alpha
(0.28)
0.1375
0.3044
N/A
(0.17)
(0.83)
(0.28)
0.1113
0.1913
(0.98)
Sortino Ratio
N/A
N/A
N/A
N/A
0.0072
N/A
N/A
0.0695
N/A
N/A
Downside Variance
N/A
N/A
N/A
N/A
21.05
N/A
N/A
26.25
N/A
N/A
Standard Deviation
1.34
5.98
6.76
N/A
4.23
4.49
7.43
4.91
1.87
4.14
Kurtosis
60.47
29.5
63.54
N/A
1.7
66.0
24.67
14.76
15.77
26.37
Potential Upside
N/A
3.85
N/A
N/A
8.0
N/A
11.11
4.35
1.75
N/A
Treynor Ratio
(0.71)
1.46
0.5486
N/A
(0.53)
1.27
0.0635
0.681
(0.58)
0.7325
Maximum Drawdown
10.71
60.76
61.69
N/A
24.19
36.46
58.78
38.34
14.74
26.47
Variance
1.8
35.74
45.67
N/A
17.88
20.14
55.25
24.11
3.5
17.1
Market Risk Adjusted Performance
(0.70)
1.47
0.5586
N/A
(0.52)
1.28
0.0735
0.691
(0.57)
0.7425
Risk Adjusted Performance
(0.10)
0.0699
0.0861
N/A
0.0232
(0.08)
0.025
0.0696
0.1281
(0.12)
Skewness
(7.68)
3.49
7.88
N/A
0.9337
(8.12)
(3.06)
2.58
3.31
(4.61)
Semi Deviation
N/A
N/A
N/A
N/A
2.89
N/A
N/A
2.92
N/A
N/A
Information Ratio
(0.19)
0.0744
0.0973
N/A
0.0078
(0.13)
0.0146
0.0725
0.1379
(0.19)
Value At Risk
N/A
N/A
N/A
N/A
(5.71)
N/A
N/A
(4.17)
N/A
(6.34)
Expected Short fall
N/A
N/A
N/A
N/A
(6.29)
N/A
N/A
(5.81)
N/A
N/A
Downside Deviation
N/A
N/A
N/A
N/A
4.59
N/A
N/A
5.12
N/A
N/A
Semi Variance
N/A
N/A
N/A
N/A
8.33
N/A
N/A
8.52
N/A
N/A

Cellectis Competition Performance Charts

Five steps to successful analysis of Cellectis Competition

Cellectis' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cellectis SA in relation to its competition. Cellectis' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Cellectis in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cellectis' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cellectis SA, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Cellectis position

In addition to having Cellectis in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Soft Drinks Thematic Idea Now

Soft Drinks
Soft Drinks Theme
Entities manufacturing and distributing non alcoholic beverages across different markets. The Soft Drinks theme has 12 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Soft Drinks Theme or any other thematic opportunities.
View All  Next Launch

Additional Information and Resources on Investing in Cellectis Pink Sheet

When determining whether Cellectis SA is a strong investment it is important to analyze Cellectis' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cellectis' future performance. For an informed investment choice regarding Cellectis Pink Sheet, refer to the following important reports:
How To Invest In Cellectis
Details
Is Cellectis Pink Sheet a good investment?
Details
What is Cellectis' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Cellectis Correlation with its peers.
You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Altman
Z Score
Details
Intrinsic
Valuation
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
It's important to distinguish between Cellectis' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cellectis should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Cellectis' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY